News Headlines Article

Promising Results Reported for Cholesterol and Hepatitis C Drugs
New York Times

New drugs for hepatitis C and superhigh cholesterol succeeded in late-stage clinical trials, the developers of the products announced on Wednesday. But both drugs have side effects that could dampen sales, analysts said.

Merck said that its drug boceprevir, when added to the existing therapy, effectively cured about two-thirds of patients with hepatitis C. That was far better than the cure rate with the existing therapy alone.